V
Vicente Estrada
Researcher at Hospital Clínico San Carlos
Publications - 162
Citations - 5636
Vicente Estrada is an academic researcher from Hospital Clínico San Carlos. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 28, co-authored 147 publications receiving 4020 citations. Previous affiliations of Vicente Estrada include Complutense University of Madrid.
Papers
More filters
Journal ArticleDOI
Risk of cardiovascular disease in patients with HIV infection undergoing antiretroviral therapy.
Vicente Estrada,Pere Domingo,I. Suarez-Lozano,Félix Gutiérrez,Hernando Knobel,Rosario Palacios,Antonio Antela,José Ramón Blanco,E. Refoyo +8 more
TL;DR: Classical CRFs are common in patients with HIV undergoing ART in Spain, and a large proportion of them have a moderate-high risk of CVD, and the use of drugs with a better cardiovascular risk profile should be assessed.
Journal ArticleDOI
Incremento del riesgo cardiovascular asociado al tratamiento antirretroviral
Journal ArticleDOI
HIV-DNA content in pTfh cells is associated with residual viremia in elite controllers.
Marcial García,Vincent Morcilla,María A Navarrete-Muñoz,Katie Fisher,Alfonso Cabello,Juan Carlos López-Bernaldo,Francisco Javier de la Hera,Carlos Castilho Barros,Manuel L. Fernández-Guerrero,Vicente Estrada,Miguel Górgolas,José Miguel Benito,Sarah Palmer,Norma Rallón +13 more
TL;DR: This association suggests that pTfh cells could have an important contribution to persistent viremia in elite controllers, a consequence of a more limited control of HIV replication in EC individuals with higher transcriptional activity of HIV in pTFh cells of EC compared to that in cART patients.
Gut Bacteria Metabolism Impacts Immune Recovery in
Sergio Serrano-Villar,D avid Rojo,Mónica Martínez-Martínez,Simon Deusch,Jorge F. Vázquez-Castellanos,Rafael Bargiela,Vicente Estrada,María José Gosalbes,Jana Seifert,Coral Barbas,Andrés Moya,Manuel Ferrer +11 more
Journal ArticleDOI
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort
Ramón Teira,Helena Diaz-Cuervo,Filipa Aragão,Manuel Castaño,Alberto Romero,Bernardino Roca,Marta Montero,María José Galindo,María-José Muñoz-Sánchez,Nuria Espinosa,Joaquim Peraire,Elisa Martínez,Belén de la Fuente,Pere Domingo,Elisabeth Deig,Maria Dolores Merino,Paloma Geijo,Vicente Estrada,Maria Sepúlveda,Josefina García García,Juan Berenguer,Adrian Curran +21 more
TL;DR: In this article , the authors compared the real-world outcomes of integrase inhibitor (INSTI)-based three-drug regimens (3DR) versus 2DR of dolutegravir (DTG) + rilpivirine (RPV) or DTG + lamivudine (3TC).